Find verified Lixisenatide API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Lixisenatide for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Lixisenatide API.
Alternate Names: Adlyxin, Lyxumia, ZP10A peptide
CAS No: 320367-13-3
PubChem CID: 90472060
Mol Formula: C215H347N61O65S
Mol Weight: 4858 g/mol
IUPAC Name: (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1- -Show More
Therapeutic use: Antidiabetic agents
Drug Class: GLP‑1 Receptor Agonists, Hypoglycemics, Peptides
Commercial / Development Status: Commercial APIs
Source / Manufacturing Origin: Peptide APIs
API Description: Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016. Lixisenatide is a GLP-1 Receptor Agonist. The mechanism of action of lixisenatide is as a Glucagon-like Peptide-1 (GLP-1) Agonist.
